Citations

Showing 10 of 108135 citations.

Faculty Opinions recommendation of Microglia enable mature perineuronal nets disassembly upon anesthetic ketamine exposure or 60-Hz light entrainment in the healthy brain.
Bosco, Dale B. , Wu, Long‐Jun

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 26, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.740425005.793587748 Get It

The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
Raffals, Laura E. , Saha, Sumona , Bewtra, Meenakshi , Norris, Cecile, Dobes, Angela , Heller, Caren, O’Charoen, Sirimon, Fehlmann, Tara, Sweeney, Sara, Weaver, Alandra, Bishu, Shrinivas , Dassopoulos, Themistocles , Fischer, Monika , Yarur, Andrés , Deepak, Parakkal , Korzenik, Joshua R. , Wells, Katerina , Bohm, Matthew , Perera, Lilani P. , Kaur, Manreet , Ciorba, Matthew A. , Scoville, Elizabeth , Dalal, Sushila , Wong, Uni , Lewis, James D. , Cross, Raymond , Caldera, Freddy , Deepak, Parakkal , Yarur, Andres J , Bishu, Shrinivas , Cross, Raymond K. , Hudesman, David , Duerr, Richard H , Caldera, Freddy , Pekow, Joel , Snapper, Scott B. , Lewis, James D

Mayo Clinic

Inflammatory Bowel Diseases | August 26, 2021 | Volume: 28 | Issue: 2 | Pages: 192-199

10.1093/ibd/izab071 | PMID 34436563 Get It

Abstract Background Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples. Methods We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized data and biosample collection methods and sample processing techniques. At enrollment and at time of lower endoscopy, patient-reported outcomes (PRO), clinical data, and endoscopy scoring indices are captured. Patient-reported outcomes are collected quarterly. The quality of clinical data entry after the first year of the study was assessed. Results Through January 2020, 3029 patients were enrolled in SPARC, of whom 66.1% have Crohn’s disease (CD), 32.2% have ulcerative colitis (UC), and 1.7% have IBD-unclassified. Among patients enrolled, 990 underwent colonoscopy. Remission rates were 63.9% in the CD group and 80.6% in the UC group. In the quality study of the cohort, there was 96% agreement on year of diagnosis and 97% agreement on IBD subtype. There was 91% overall agreement describing UC extent as left-sided vs extensive or pancolitis. The overall agreement for CD behavior was 83%. Conclusion The SPARC IBD is an ongoing large prospective cohort with longitudinal standardized collection of clinical data, biosamples, and PROs representing a unique resource aimed to drive discovery of clinical and molecular markers that will meet the needs of precision medicine in IBD.
Expanding the phenotype of ASXL3‐related syndrome: A comprehensive description of 45 unpublished individuals with inherited and de novo pathogenic variants in ASXL3
Schirwani, Schaida , Albaba, Shadi , Carere, Deanna Alexis , Sacoto, María J. Guillen , Zamora, Francisca Milan, Si, Yue , Rabin, Rachel , Renaud, Deborah L. , Hauser, Natalie , Blanchet, Patricia, Foulds, Nichola, Dixit, Abhijit , Fisher, Richard, Armstrong, Ruth, Isidor, Bertrand , Demirdas, Serwet , Dykzeul, Natalie, Cohen, Julie S. , Grand, Katheryn , Swols, Dayna Morel , Albassam, Hessa F., Naik, Swati , Ragge, Nicola , Tedesco, Maria Giovanna , Harrison, Rachel , Bouman, Arjan , Palen, Emily, Challman, Thomas D. , Willemsen, Marjolein H. , Vogt, Julie , Cunniff, Christopher , Bergstrom, Katherine , Bruel, Ange‐Line , Kini, Usha , Alkuraya, Fowzan S. , Slegesky, Valerie, Meeks, Naomi, Girotto, Paula Natale , Johnson, Diana , Study, DDD, Newbury‐Ecob, Ruth , Lynch, Sally Ann , Graham, John M. , Balasubramanian, Meena , Hauser, Natalie , Schrier Vergano, Samantha , Bouman, Arjan , Cunniff, Christopher , Bergstrom, Katherine , Bruel, Ange-Line , Alkuraya, Fowzan S , Prontera, Paolo , Li, Dong , Graham, John M , Zamora, Francisca Millan, Pappas, John , Reid, Evan , Cogné, Benjamin , Vergano, Samantha A. Schrier , Slavotinek, Anne , Naik, Swati, Dean, John , Costa, Cinzia , Walia, Jagdeep Singh , Study, DDD, Ockeloen, Charlotte W. , Li, Dong , Pierson, Tyler Mark

Mayo Clinic

American Journal of Medical Genetics Part A | August 26, 2021 | Volume: 185 | Issue: 11 | Pages: 3446-3458

10.1002/ajmg.a.62465 | PMID 34436830 Get It

AbstractThe study aimed at widening the clinical and genetic spectrum of ASXL3‐related syndrome, a neurodevelopmental disorder, caused by truncating variants in the ASXL3 gene. In this international collaborative study, we have undertaken a detailed clinical and molecular analysis of 45 previously unpublished individuals with ASXL3‐related syndrome, as well as a review of all previously published individuals. We have reviewed the rather limited functional characterization of pathogenic variants in ASXL3 and discuss current understanding of the consequences of the different ASXL3 variants. In this comprehensive analysis of ASXL3‐related syndrome, we define its natural history and clinical evolution occurring with age. We report familial ASXL3 pathogenic variants, characterize the phenotype in mildly affected individuals and discuss nonpenetrance. We also discuss the role of missense variants in ASXL3. We delineate a variable but consistent phenotype. The most characteristic features are neurodevelopmental delay with consistently limited speech, significant neuro‐behavioral issues, hypotonia, and feeding difficulties. Distinctive features include downslanting palpebral fissures, hypertelorism, tubular nose with a prominent nasal bridge, and low‐hanging columella. The presented data will inform clinical management of individuals with ASXL3‐related syndrome and improve interpretation of new ASXL3 sequence variants.
Matrix Hyaluronic Acid and Hypoxia Influence a CD133 + Subset of Patient-Derived Glioblastoma Cells
Chen, Jee-Wei Emily , Barnhouse, Victoria R., Leary, Sarah , Sarkaria, Jann N. , Harley, Brendan A.C.

Mayo Clinic

Tissue Engineering Part A | August 26, 2021 | Volume: 28 | Issue: 7-8 | Pages: 330-340

10.1089/ten.tea.2021.0117 | PMID 34435883 Get It

Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis
Sethi, Sanjeev , Sethi, Sanjeev , Moura, Marta Casal , Fervenza, Fernando C. , Specks, Ulrich

Mayo Clinic

Nephrology Dialysis Transplantation | August 26, 2021 | Volume: 37 | Issue: 9 | Pages: 1710-1721

10.1093/ndt/gfab250 | PMID 34436585 Get It

Abstract Background Kidney biopsy is valuable for prognostic assessment of renal outcomes in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with glomerulonephritis (AAV-GN) but the impact of chronic changes is not determined. Methods We conducted a retrospective cohort study of myeloperoxidase (MPO)- or proteinase 3 (PR3)-ANCA-positive patients with AAV and active renal disease. We applied the Mayo Clinic Chronicity Score (MCCS) and validated and evaluated its implications on outcome prediction in AAV-GN. Results We analyzed 329 patients with kidney biopsies available to score. The extent of chronicity was graded by MCCS as minimal [102 (31.0%)], mild [106 (32.2%)], moderate [86 (26.1%)] and severe [35 (10.6%)]. The MCCS grades correlated with the degree of renal function impairment at presentation [mean estimated glomerular filtration rate (eGFR) 48.3 versus 29.2 versus 23.7 versus 18.5 mL/min/1.73 m2, respectively; P < 0.0001]. Higher degrees of the individual components of the MCCS (glomerulosclerosis, interstitial fibrosis, tubular atrophy and arteriosclerosis) were associated with lower median eGFR (P < 0.0001) and decreased event-free [kidney failure (KF) and death] survival (P = 0.002, P < 0.0001, P < 0.0001 and P = 0.017, respectively). Patients with lower MCCS grades recovered renal function more frequently (P < 0.0001). Increasing MCCS grades were associated with decreased renal recovery (P = 0.001), more frequent events and shorter time to KF (P < 0.0001), KF and death (P < 0.0001) and death (P = 0.042), independent of the remission induction treatment used (cyclophosphamide or rituximab). The MCCS stratified renal outcomes for each MCCS grade and can be used in clinical practice as a cutoff for KF prediction (MCCS ≥4). Conclusions Chronic changes on kidney histology independently predict renal function, outcomes and response to treatment in AAV-GN.
Outcome Following Hemorrhage From Cranial Dural Arteriovenous Fistulae
Koch, Matthew J. , Stapleton, Christopher J. , Guniganti, Ridhima , Lanzino, Giuseppe , Sheehan, Jason P. , Alaraj, Ali , Bulters, Diederik , Kim, Louis J. , Fox, W. Christopher , Gross, Bradley A. , Hayakawa, M. , Dijk, J. Marc C. van , Starke, Robert M., Satomi, Junichiro, Polifka, Adam , Zipfel, Gregory J. , Amin‐Hanjani, Sepideh , Derdeyn, Colin P. , Sheehan, Jason , Kim, Louis J. , van DijK, J Marc C , Amin-Hanjani, Sepideh , Alaraj, Ali , Fox, W Christopher , Lanzino, Giuseppe , Bulters, Diederik O , Derdeyn, Colin P , Gross, Bradley

Mayo Clinic

Stroke | August 26, 2021 | Volume: 52 | Issue: 10 | Pages: No page available

10.1161/strokeaha.121.034707 | PMID 34433307 Get It

Background and Purpose: Dural arteriovenous fistulae can present with hemorrhage, but there remains a paucity of data regarding subsequent outcomes. We sought to use the CONDOR (Consortium for Dural Arteriovenous Fistula Outcomes Research), a multi-institutional registry, to characterize the morbidity and mortality of dural arteriovenous fistula–related hemorrhage. Methods: A retrospective review of patients in CONDOR who presented with dural arteriovenous fistula–related hemorrhage was performed. Patient characteristics, clinical follow-up, and radiographic details were analyzed for associations with poor outcome (defined as modified Rankin Scale score ≥3). Results: The CONDOR dataset yielded 262 patients with incident hemorrhage, with median follow-up of 1.4 years. Poor outcome was observed in 17.0% (95% CI, 12.3%–21.7%) at follow-up, including a 3.6% (95% CI, 1.3%–6.0%) mortality. Age and anticoagulant use were associated with poor outcome on multivariable analysis (odds ratio, 1.04, odds ratio, 5.1 respectively). Subtype of hemorrhage and venous shunting pattern of the lesion did not affect outcome significantly. Conclusions: Within the CONDOR registry, dural arteriovenous fistula–related hemorrhage was associated with a relatively lower morbidity and mortality than published outcomes from other arterialized cerebrovascular lesions but still at clinically consequential rates.
Gastropericardial Fistula After Unconventional Venting Gastrostomy Placement in Encapsulating Peritoneal Sclerosis
Vinsard, Daniela Guerrero , Vinsard, Patrice A , Guerrero Vinsard, Daniela , Vinsard, Patrice, Vinsard, Patrice

Mayo Clinic

American Journal of Gastroenterology | August 26, 2021 | Volume: 117 | Issue: 1 | Pages: 17-17

10.14309/ajg.0000000000001489 | PMID 34435974 Get It

The treatment of anogenital extramammary Paget's disease as part of a multidisciplinary approach: The use of Mohs surgery moat method with CK7
Brough, Kevin, Carley, Sama K. , Vidal, Nahid Y.

Mayo Clinic

International Journal of Dermatology | August 26, 2021 | Volume: 61 | Issue: 2 | Pages: 238-245

10.1111/ijd.15847 | PMID 34435670 Get It

Abstract Although most cases of extramammary Paget's disease (EMPD) are localized to the intraepidermal, the extensive subclinical extension can lead to high rates of marginal recurrence with wide local excisions and topically destructive treatments. Recurrence rates of EMPD treated with Mohs micrographic surgery (MMS) without immunohistochemical staining are better but variable. Here, we describe our multidisciplinary approach for treating large EMPD tumors of the anogenital region involving critical anatomy using MMS for peripheral margin clearance (moat method) and intraoperative CK7 immunostaining. Our clinical pearls for the management of anogenital EMPD are based on 53 multidisciplinary cases treated at the author's institution between 2014 and 2020.
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
Majzoub, Abdul M., Nayfeh, Tarek , Barnard, Abbey, Munaganuru, Nagambika, Dave, Shravan , Singh, Siddharth , Loomba, Rohit , Murad, Mohammad Hassan, Loomba, Rohit , Nayfeh, Tarek , Murad, M. Hassan

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 26, 2021 | Volume: 54 | Issue: 7 | Pages: 880-889

10.1111/apt.16583 | PMID 34435378 Get It

SummaryBackgroundNonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease. There is a major need to understand the efficacy of different pharmacological agents for the treatment of NASH.AimTo assess the relative rank‐order of different pharmacological interventions in fibrosis improvement and NASH resolution.MethodsA comprehensive search of several databases was conducted by an experienced librarian. We included randomised controlled‐trials (RCTs) comparing pharmacological interventions in patients with biopsy‐proven NASH. The primary outcome was ≥1 stage improvement in fibrosis. The secondary outcome was NASH resolution.ResultsA total of 26 RCTs with 23 interventions met the eligibility criteria. Lanifibranor and obeticholic acid had the highest probability of being ranked the most effective intervention for achieving ≥1 stage of fibrosis improvement (SUCRA 0.78) and (SUCRA 0.77), respectively. For NASH resolution, semaglutide, liraglutide and vitamin E plus pioglitazone had the highest probability of being ranked the most effective intervention for achieving NASH resolution (SUCRA 0.89), (SUCRA 0.84) and (SUCRA 0.83), respectively. Lanifibranor, obeticholic acid, pioglitazone and vitamin E were significantly better than placebo in achieving ≥1 stage of fibrosis improvement. Conversely, semaglutide, liraglutide, vitamine E plus pioglitazone, pioglitazone, lanifibranor and obeticholic acid were significantly better than placebo in achieving NASH resolution.ConclusionThese data provide relative rank‐order efficacy of various NASH therapies in terms of their improvements in liver fibrosis and NASH resolution. Therapies that have been shown to improve NASH resolution may be combined with therapies that have an antifibrotic effect to further boost treatment response rate in future.